Literature DB >> 25681307

End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.

Warren P Mason1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25681307      PMCID： PMC4482863          DOI： 10.1093/neuonc/nov018

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  13 in total

1.  Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.

Authors:  Shinya Yamada; Xing-Yao Bu; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; J Gordon McComb; Walter E Laug
Journal:  Neurosurgery       Date:  2006-12       Impact factor: 4.654

2.  Cilengitide induces autophagy-mediated cell death in glioma cells.

Authors:  Stephanie L Lomonaco; Susan Finniss; Cunli Xiang; Hae Kyung Lee; Wei Jiang; Nancy Lemke; Sandra A Rempel; Tom Mikkelsen; Chaya Brodie
Journal:  Neuro Oncol       Date:  2011-07-25       Impact factor: 12.300

3.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Authors:  Roger Stupp; Monika E Hegi; Bart Neyns; Roland Goldbrunner; Uwe Schlegel; Paul M J Clement; Gerhard G Grabenbauer; Adrian F Ochsenbein; Matthias Simon; Pierre-Yves Dietrich; Torsten Pietsch; Christine Hicking; Joerg-Christian Tonn; Annie-Claire Diserens; Alessia Pica; Mirjam Hermisson; Stefan Krueger; Martin Picard; Michael Weller
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

4.  Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death.

Authors:  J H Uhm; N P Dooley; A P Kyritsis; J S Rao; C L Gladson
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

Review 5.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

6.  Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.

Authors:  L Bello; M Francolini; P Marthyn; J Zhang; R S Carroll; D C Nikas; J F Strasser; R Villani; D A Cheresh; P M Black
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

7.  Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Authors:  L Burt Nabors; Karen L Fink; Tom Mikkelsen; Danica Grujicic; Rafal Tarnawski; Do Hyun Nam; Maria Mazurkiewicz; Michael Salacz; Lynn Ashby; Vittorina Zagonel; Roberta Depenni; James R Perry; Christine Hicking; Martin Picard; Monika E Hegi; Benoit Lhermitte; David A Reardon
Journal:  Neuro Oncol       Date:  2015-03-11       Impact factor: 12.300

8.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Authors:  L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

9.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

Authors:  David A Reardon; Karen L Fink; Tom Mikkelsen; Timothy F Cloughesy; Alison O'Neill; Scott Plotkin; Michael Glantz; Paula Ravin; Jeffrey J Raizer; Keith M Rich; David Schiff; William R Shapiro; Susan Burdette-Radoux; Edward J Dropcho; Sabine M Wittemer; Johannes Nippgen; Martin Picard; L Burt Nabors
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

Review 10.  Cilengitide Merck.

Authors:  Jeffrey W Smith
Journal:  Curr Opin Investig Drugs       Date:  2003-06
View more
  19 in total

1.  Structural Basis of the Differential Binding of Engineered Knottins to Integrins αVβ3 and α5β1.

Authors:  Johannes F Van Agthoven; Hengameh Shams; Frank V Cochran; José L Alonso; James R Kintzing; Kiavash Garakani; Brian D Adair; Jian-Ping Xiong; Mohammad R K Mofrad; Jennifer R Cochran; M Amin Arnaout
Journal:  Structure       Date:  2019-07-25       Impact factor: 5.006

2.  Adaptive adhesion systems mediate glioma cell invasion in complex environments.

Authors:  Pavlo G Gritsenko; Peter Friedl
Journal:  J Cell Sci       Date:  2018-08-13       Impact factor: 5.285

3.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

4.  Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine.

Authors:  Joanna Klubo-Gwiezdzinska; Xiaoyuan Chen
Journal:  Thyroid       Date:  2020-04       Impact factor: 6.568

Review 5.  Tumor exosomes: a double-edged sword in cancer therapy.

Authors:  Wei Sun; Ju-Dong Luo; Hua Jiang; Dayue Darrel Duan
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

6.  Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Authors:  Érika Cosset; Sten Ilmjärv; Valérie Dutoit; Kathryn Elliott; Tami von Schalscha; Maria F Camargo; Alexander Reiss; Toshiro Moroishi; Laetitia Seguin; German Gomez; Jung-Soon Moo; Olivier Preynat-Seauve; Karl-Heinz Krause; Hervé Chneiweiss; Jann N Sarkaria; Kun-Liang Guan; Pierre-Yves Dietrich; Sara M Weis; Paul S Mischel; David A Cheresh
Journal:  Cancer Cell       Date:  2017-11-30       Impact factor: 31.743

Review 7.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

8.  Transformed MDCK cells secrete elevated MMP1 that generates LAMA5 fragments promoting endothelial cell angiogenesis.

Authors:  Shashi K Gopal; David W Greening; Hong-Jian Zhu; Richard J Simpson; Rommel A Mathias
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

Review 9.  Every step of the way: integrins in cancer progression and metastasis.

Authors:  Hellyeh Hamidi; Johanna Ivaska
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

10.  A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.

Authors:  Geert A Cirkel; Bojana Milojkovic Kerklaan; Frédéric Vanhoutte; Annegret Van der Aa; Giocondo Lorenzon; Florence Namour; Philippe Pujuguet; Sophie Darquenne; Filip Y F de Vos; Tom J Snijders; Emile E Voest; Jan H M Schellens; Martijn P Lolkema
Journal:  Invest New Drugs       Date:  2016-01-20       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.